---
title: "VK2735 in Chronic weight management: Other anti-obesity medications"
description: "Formulary evidence on VK2735 in Chronic weight management: Other anti-obesity medications. Topics: AGA guideline recommendations for pharmacotherapy, Endocrine Society guideline on medications as adjuncts to lifestyle change, Weight loss with older anti-obesity medications in the ADA Standards of Care, Duration of approval for phentermine and other older adrenergic agents, and 2 further topics. 6 evidence topics quoted from 6 sources."
canonical: "https://www.evicenter.com/drugs/vk2735--chronic-weight-management/product-information-and-disease-description/other-anti-obesity-medications"
published: "2026-11-15T21:45:47-05:00"
modified: "2026-11-15T21:45:47-05:00"
---

# VK2735 in Chronic weight management: Other anti-obesity medications

<a id="heading-2.2.2.1.5"></a>

## 2.2.2.1.5 Other Anti-obesity Medications

<a id="topic-2.2.2.1.5-1"></a>

### AGA guideline recommendations for pharmacotherapy

> “The panel strongly recommended the use of pharmacotherapy in addition to lifestyle intervention in adults with overweight and obesity (body mass index ≥30 kg/m2, or ≥27 kg/m2 with weight-related complications) who have an inadequate response to lifestyle interventions.”
> “The panel suggested the use of semaglutide 2.4 mg, liraglutide 3.0 mg, phentermine-topiramate ER, and naltrexone-bupropion ER (based on moderate certainty evidence), and phentermine and diethylpropion (based on low certainty evidence), for long-term management of overweight and obesity.”
> “The guideline panel suggested against the use of orlistat.”

Source: [Grunvald et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/36273831/)

<a id="topic-2.2.2.1.5-2"></a>

### Endocrine Society guideline on medications as adjuncts to lifestyle change

> “Medications approved for chronic weight management can be useful adjuncts to lifestyle change for patients who have been unsuccessful with diet and exercise alone.”

Source: [Apovian et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/25590212/)

<a id="topic-2.2.2.1.5-3"></a>

### Weight loss with older anti-obesity medications in the ADA Standards of Care

| Medication | Active treatment arm; weight loss from baseline | Placebo; weight loss from baseline | Trial duration (weeks) |
| --- | --- | --- | --- |
| Phentermine | “15 mg q.d.; 7.4%” | “Placebo; 2.3%” | “28” |
| Phentermine/topiramate ER | “15 mg/92 mg q.d.; 9.8%” | “Placebo; 1.2%” | “56” |
| Naltrexone/bupropion ER | “16 mg/180 mg b.i.d.; 5%” | “Placebo; 1.8%” | “56” |
| Orlistat | “120 mg t.i.d.; 9.6%” | “Placebo; 5.6%” | “52” |

Source: [American Diabetes Association Professional Practice Committee (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12690172/)

<a id="topic-2.2.2.1.5-4"></a>

### Duration of approval for phentermine and other older adrenergic agents

> “Phentermine and other older adrenergic agents are approved for short-term treatment (112), while all others are approved for long-term treatment (Tables 8.1 and 8.2).”
> “As monotherapy, phentermine is only approved for short-term use.”

Source: [American Diabetes Association Professional Practice Committee (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12690172/)

<a id="topic-2.2.2.1.5-5"></a>

### Phentermine plus topiramate: CONQUER primary results at week 56

> “At 56 weeks, change in bodyweight was -1·4 kg (least-squares mean -1·2%, 95% CI -1·8 to -0·7), -8·1 kg (-7·8%, -8·5 to -7·1; p<0·0001), and -10·2 kg (-9·8%, -10·4 to -9·3; p<0·0001) in the patients assigned to placebo, phentermine 7·5 mg plus topiramate 46·0 mg, and phentermine 15·0 mg plus topiramate 92·0 mg, respectively.”
> “The most common adverse events were dry mouth (24 [2%], 67 [13%], and 207 [21%] in the groups assigned to placebo, phentermine 7·5 mg plus topiramate 46·0 mg, and phentermine 15·0 mg plus topiramate 92·0 mg, respectively), paraesthesia (20 [2%], 68 [14%], and 204 [21%], respectively)”

Source: [Gadde et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/21481449/)

<a id="topic-2.2.2.1.5-6"></a>

### Naltrexone plus bupropion: COR-I primary results at week 56

> “Mean change in bodyweight was -1.3% (SE 0.3) in the placebo group, -6.1% (0.3) in the naltrexone 32 mg plus bupropion group (p<0.0001 vs placebo) and -5.0% (0.3) in the naltrexone 16 mg plus bupropion group (p<0.0001 vs placebo).”
> “870 (50%) participants completed 56 weeks of treatment (n=296; n=284; n=290, respectively)”

Source: [Greenway et al. (2010)](https://pubmed.ncbi.nlm.nih.gov/20673995/)

Additional sources: [Torgerson et al. (2004)](https://pubmed.ncbi.nlm.nih.gov/14693982/)

## Related pages
- [VK2735: Chronic weight management](https://www.evicenter.com/drugs/vk2735--chronic-weight-management) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management.md)
- [VK2735 in Chronic weight management: Terms and abbreviations](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/terms-and-abbreviations.md)
- [VK2735: Chronic weight management](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/executive-summary) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/executive-summary.md)
- [VK2735 in Chronic weight management: Product information and disease description](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/product-information-and-disease-description.md)
- [VK2735 in Chronic weight management: Clinical evidence](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/clinical-evidence.md)
- [VK2735 in Chronic weight management: Economic information and modeling report](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/economics) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/economics.md)
- [VK2735 in Chronic weight management: References](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/references) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/references.md)
